Vaxart, Inc. (VXRT) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2024-09-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2024-09-30..
Cash and securities
Overview →Financial period ending 2024-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2024-09-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2024-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 22.04M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Available-for-sale Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2024-09-30 | (m) | (m) | $22.04M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $26.73M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $34.76M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $33.16M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $46.83M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $44.01M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $143.75M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $19.60M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $16.30M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $8.40M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $11.51M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $17.92M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $23.92M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $17.50M | (m) | (m) |
| 2017-12-31 | $48.10M | (m) | $29.40M | $18.70M | (m) |
| 2017-09-30 | $51.10M | (m) | $19.60M | $31.50M | (m) |
| 2017-06-30 | $49.50M | (m) | $17.70M | $31.80M | (m) |
| 2017-03-31 | $45.00M | (m) | $11.80M | $33.20M | (m) |
| 2016-12-31 | $59.90M | (m) | $38.10M | $21.80M | (m) |
| 2016-09-30 | $67.70M | (m) | $45.90M | $21.80M | (m) |
| 2016-06-30 | $70.50M | (m) | $49.70M | $20.80M | (m) |
| 2016-03-31 | $76.20M | (m) | $30.60M | $45.60M | (m) |
| 2015-12-31 | (m) | (m) | $39.00M | (m) | (m) |
| 2015-09-30 | $72.40M | (m) | $45.30M | $27.10M | (m) |
| 2015-06-30 | $71.80M | (m) | $44.70M | $27.10M | (m) |
| 2015-03-31 | $95.60M | (m) | $61.50M | $34.10M | (m) |
| 2014-12-31 | $103.50M | (m) | $63.70M | $39.80M | (m) |
| 2014-09-30 | $101.00M | (m) | $57.70M | $43.30M | (m) |
| 2014-06-30 | (m) | (m) | $81.70M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $80.10M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $51.40M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $60.80M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $66.80M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $70.27M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $74.11M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $66.32M | (m) | (m) |
| 2012-06-30 | (m) | (m) | $92.65M | (m) | (m) |
| 2012-03-31 | (m) | (m) | $94.88M | (m) | (m) |
| 2011-12-31 | $96.39M | (m) | $94.31M | $2.08M | (m) |
| 2011-09-24 | $102.01M | (m) | $92.95M | $9.06M | (m) |
| 2011-06-30 | (m) | (m) | $74.18M | (m) | (m) |
| 2011-06-25 | $102.32M | (m) | $86.62M | $15.71M | (m) |
| 2011-03-26 | (m) | (m) | $59.09M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $53.56M | (m) | (m) |
| 2010-12-25 | $108.17M | (m) | $53.56M | $54.60M | (m) |
| 2010-09-25 | (m) | (m) | $37.28M | (m) | (m) |
| 2010-06-30 | (m) | (m) | $89.80M | (m) | (m) |
| 2010-06-26 | (m) | (m) | $32.45M | (m) | (m) |
| 2009-12-26 | (m) | (m) | $59.51M | (m) | (m) |
| 2008-12-27 | (m) | (m) | $106.44M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |